Carregant...
Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum?
IgA nephropathy (IgAN) is characterized by a variable clinical course and multifaceted pathophysiology. There is substantial evidence to suggest that complement activation plays a pivotal role in the pathogenesis of the disease. Therefore, complement inhibition using the humanized anti-C5 monoclonal...
Guardat en:
| Publicat a: | Clin Kidney J |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4581393/ https://ncbi.nlm.nih.gov/pubmed/26413271 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfv076 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|